John Roberts, exiting Vyant Bio CEO

Neu­rode­gen­er­a­tive biotech Vyant warns of po­ten­tial wind-down

The CEO and chief sci­en­tif­ic of­fi­cer of Vyant Bio are out the door as the lit­tle-known but pub­licly-list­ed neu­rode­gen­er­a­tive biotech search­es for an ex­it or, if all else fails, a wind-down.

The soul-search­ing book­ends a wind­ing jour­ney for the biotech, which re­brand­ed and tran­si­tioned from di­ag­nos­tics com­pa­ny Can­cer Ge­net­ics in 2021 af­ter a merg­er with Ste­moniX. That came af­ter a failed merg­er at­tempt with Nov­el­lus­Dx (now Fore Bio­ther­a­peu­tics) in 2018. In the last few years, units have been sold off and the stock price $VYNT has plum­met­ed from the $30 range to pen­ny stock ter­ri­to­ry.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.